D. Boral Capital Reiterates “Buy” Rating for ImmunityBio (NASDAQ:IBRX)

D. Boral Capital restated their buy rating on shares of ImmunityBio (NASDAQ:IBRX) in a research report report published on Friday morning,Benzinga reports. They currently have a $30.00 target price on the stock.

A number of other research analysts also recently issued reports on IBRX. EF Hutton Acquisition Co. I raised ImmunityBio to a “strong-buy” rating in a report on Wednesday, October 23rd. BTIG Research began coverage on ImmunityBio in a report on Friday, January 10th. They issued a “buy” rating and a $6.00 price target for the company.

ImmunityBio Stock Up 9.0 %

ImmunityBio stock opened at $3.62 on Friday. ImmunityBio has a 52 week low of $2.28 and a 52 week high of $10.53. The stock has a 50-day moving average price of $3.00 and a 200 day moving average price of $3.83.

Institutional Trading of ImmunityBio

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Wealth Effects LLC increased its position in shares of ImmunityBio by 3.4% in the third quarter. Wealth Effects LLC now owns 90,500 shares of the company’s stock valued at $337,000 after buying an additional 3,000 shares in the last quarter. Exchange Traded Concepts LLC increased its position in shares of ImmunityBio by 8.4% in the third quarter. Exchange Traded Concepts LLC now owns 47,984 shares of the company’s stock valued at $178,000 after buying an additional 3,722 shares in the last quarter. Swiss National Bank increased its position in shares of ImmunityBio by 1.5% in the fourth quarter. Swiss National Bank now owns 274,000 shares of the company’s stock valued at $701,000 after buying an additional 4,000 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of ImmunityBio by 22.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company’s stock valued at $99,000 after buying an additional 4,545 shares in the last quarter. Finally, Teacher Retirement System of Texas increased its position in shares of ImmunityBio by 20.4% in the fourth quarter. Teacher Retirement System of Texas now owns 41,742 shares of the company’s stock valued at $107,000 after buying an additional 7,067 shares in the last quarter. 8.58% of the stock is currently owned by hedge funds and other institutional investors.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.